SOURCE: Addison-Davis Diagnostics, Inc.

July 12, 2005 08:30 ET

Addison-Davis Diagnostics to Target $2.2 Billion Substance Abuse Market With Drug Stop

WESTLAKE VILLAGE, CA -- (MARKET WIRE) -- July 12, 2005 -- Addison-Davis Diagnostics, Inc. (OTC BB: ADDI) is pleased to announce that they will be targeting the $2.2 Billion substance abuse market with their Drug Stop product. The Drug Stop product has received a 510(K) FDA Clearance for the test as well as FDA clearance for sale to the Over-The-Counter market.

The Company plans to take advantage of various State incentive programs for a "Drug Free Workplace." The Government's Drug Free Workplace initiative's biggest incentive is to offer Workers Compensation Insurance Discounts to Companies that have mandatory drug testing. Addison-Davis believes these incentives will open corporations to implementing drug testing programs.

Addison-Davis has selected the substance abuse market (drugs and alcohol) as its initial priority target market. This market is estimated to be over $2.2 Billion. Recent studies show that illicit drug use is as equally implicated as alcohol in DUI arrests in the United States and 65-85% of the DUI problem in Europe. In 1997, in the U.S., 73% of all illegal drug users were employed and more than 14% of American workers had a drug or alcohol abuse problem. Drugs and alcohol use have been implicated in up to 50% of all emergency room trauma visits in the United States. Police officers making traffic stops, emergency room doctors and nurses, and employers sending workers out in trucks, trains and planes all need a test to provide an immediate indication of performance "under-the-influence."

About Addison-Davis

Addison-Davis Diagnostics, Inc. is responding to industry demands by supplying quick response diagnostic tests that are user friendly, produce fast simple results and are less costly, less problematic and less time consuming. Addison-Davis is currently focused on bringing fast and reliable "Point-of-care" Diagnostic Testing through the use of its patented technology to Healthcare Professionals, Hospitals, certain branches of the Government and the Workplace environment for drugs-of-abuse and medical conditions and diseases.

For more information please visit our website or contact Matt Maguire 1-866 THE APPL(E)

Safe Harbor

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact Information